UAMS BioVentures Company Set To Go Public

by Mark Friedman  on Monday, Apr. 22, 2013 12:00 am  

Cyto Wave Technologies hopes to use this iV3 prototype to detect and kill cancer cells.  Vladimir Zharov, inset, developed the device with others

Favorable trials are keys to the company moving forward.

“We will be able to fund the first stage of our clinical trails with cash on hand,” the company said in its filing. At the end of 2012, Cyto Wave had $948,445 in cash.

“But if any stage of our clinical trials produces ambiguous or unfavorable results, it is unlikely that we will be able to raise additional funds for subsequent stages and our business will fail and our stock will become virtually worthless,” the company said. 

The trials are expected to finish in August. “We’ll know more once these trials come out,” Chisenhall said.

 

 

Please read our comments policy before commenting.